A comprehensive view of Generics / Biosimilars. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.
FTC files an amicus brief alleging that Teva improperly listed patents on its ProAir HFA asthma inhaler in the FDA Orange Book, blocking Amneal's approval for a generic version; the FTC is seeking a court judgement to make Teva retract the patents
Published:
March 25, 2024
by FiercePharma
|
Cardinal Health focuses on biosimilars to lower healthcare costs and revolutionize treatment access; operations consolidate in Central Ohio for better service delivery and market expansion
Published:
March 21, 2024
by Industry Intelligence Inc.
|
Biocon Biologics settles patent disputes with Bayer and Regeneron, can launch YESAFILI biosimilar in Canada by July 2025
Published:
March 15, 2024
by Mondaq Business Briefing
|
Celltrion submits BLA for CT-P39, a biosimilar version of Xolair, to US FDA for treatment of multiple conditions including asthma and food allergies; submission backed by data demonstrating comparable efficacy and safety
Published:
March 11, 2024
by PharmaShots
|
FDA approves Fresenius Kabi's Tyenne, a biosimilar tocilizumab drug for inflammatory and immune diseases referencing Actemra tocilizumab in both IV and subcutaneous formulations; this marks the company's third biosimilar approval in the US
Published:
March 08, 2024
by ENP Newswire
|
Ask us about our Tissue & Hygiene market view